Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases

A Population-Based Cohort Study

Bibliographic Data

ID15480496
AuthorsKai Wang (0000-0002-3784-1378, Department of Ophthalmology, Cathay General Hospital, Taipei 106, Taiwan), Ming‐Ju Hsieh (0000-0001-9726-3234, China Medical University), Hsiang‐Wen Chien (Cathay General Hospital), Hsiang-Wen Chien (Department of Ophthalmology, Cathay General Hospital, Taipei 106, Taiwan), Chia‐Yi Lee (0000-0002-5719-0488, Chang Bing Show Chwan Memorial Hospital), Chao‐Bin Yeh (0000-0002-3978-5576, Chung Shan Medical University Hospital), Jing‐Yang Huang (0000-0002-0794-9388, Chung Shan Medical University Hospital), Shun‐Fa Yang (0000-0002-0365-7927, Chung Shan Medical University Hospital, corresponding author)
Year2021
Volume18
Issue1
Pages301-301
Publication date2021-01-03
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph18010301
PMID33401577
OpenAlexW3119541522
LanguageEN
References cited37

The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887, p = 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909, p = 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906, p = 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934, p = 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD

Cohort · Confidence interval · Dyslipidemia · Environmental health · Fibrate · Hazard ratio · Incidence (geometry · Macular degeneration · Obesity · Population · Proportional hazards model · Risk factor · Statin · Medicine · Retinal and Optic Conditions · Retinal Diseases and Treatments · Retinal Imaging and Analysis · Internal Medicine · Ophthalmology

Tools

Open DOIOpen Access